TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30020401

Group type: EXPERIMENTAL
Intervention: Moderate volume aerobic exercise (150 min/week)
Number of subjects: 400

Group type: COMPARATOR
Intervention: High volume aerobic exercise (300 min/week)
Number of subjects: 400

Group type: COMPARATOR
Intervention: Women working full time
Number of subjects: 400

Group type: COMPARATOR
Intervention: Increase in BMI by 1 kg/m2
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Increase in physical health
Number of subjects: 400
Study: 28109107

Group type: EXPERIMENTAL
Intervention: rTMS treatment
Number of subjects: 178

Group type: COMPARATOR
Intervention: Sham rTMS treatment (Control)
Number of subjects: 178
Study: 26056438

Group type: EXPERIMENTAL
Intervention: Low-threshold physical activity program (60 minutes weekly for 20 weeks)
Number of subjects: 222

Group type: COMPARATOR
Intervention: Control group (no intervention specified)
Number of subjects: 222
Study: 22680774

Group type: EXPERIMENTAL
Intervention: Intensive chemotherapy (i.v., mg/m(2), vindesine 5, adriamycin 90, BCNU 140, etoposide 600, methylprednisolone 600) before radiotherapy (RT)
Number of subjects: 269

Group type: EXPERIMENTAL
Intervention: Three or four cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) followed by RT
Number of subjects: 269

Group type: COMPARATOR
Intervention: Historical control group (HCG) in CR after three ABVD cycles before RT
Number of subjects: 269
Study: 22232850

Group type: EXPERIMENTAL
Intervention: Etoricoxib 60 mg (test product: Etocox-60)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Etoricoxib 60 mg (reference product)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Etoricoxib 60 mg (test product: Etocox-60) and reference product
Number of subjects: 24
Study: 19770831

Group type: EXPERIMENTAL
Intervention: Cavinton 30 mg/day for 90 days (2 courses per year) in addition to basic therapy
Number of subjects: 138

Group type: COMPARATOR
Intervention: Basic therapy only
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: Cavinton treatment
Number of subjects: 138
Study: 16478572

Group type: EXPERIMENTAL
Intervention: GDS-30 (cut-off 14/15)
Number of subjects: 392

Group type: COMPARATOR
Intervention: Classical GHQ (cut-off 4/5)
Number of subjects: 392

Group type: COMPARATOR
Intervention: Likert GHQ (cut-off 15/16)
Number of subjects: 392

Group type: COMPARATOR
Intervention: c-GHQ (cut-off 5/6)
Number of subjects: 392
Study: 12044619

Group type: EXPERIMENTAL
Intervention: Sustained-release morphine (20mg/d titrated to a maximum of 180mg/d)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study: 10210123

Group type: EXPERIMENTAL
Intervention: Hispanic live births
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-Hispanic European live births
Number of subjects: 0
Study: 7842195

Group type: EXPERIMENTAL
Intervention: Oxygen therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dopamine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both therapies (Oxygen and Dopamine)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (Air)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oxygen
Number of subjects: 0
Study: 2371429

Group type: EXPERIMENTAL
Intervention: Oscillometry
Number of subjects: 27

Group type: COMPARATOR
Intervention: Passive anterior rhinomanometry
Number of subjects: 27

Group type: COMPARATOR
Intervention: Active anterior rhinomanometry
Number of subjects: 27

Group type: COMPARATOR
Intervention: Active posterior rhinomanometry
Number of subjects: 27
Study: 731810

Group type: EXPERIMENTAL
Intervention: estramustine-17-phosphate (600 mg daily for at least 3 months)
Number of subjects: 0

Group type: COMPARATOR
Intervention: 2.6‐cis-diphenylhexamethylcyclotetrasiloxane (300 mg daily for at least 3 months)
Number of subjects: 0

Group type: COMPARATOR
Intervention: 2.6‐cis-diphenylhexamethylcyclotetrasiloxane (non-randomized group)
Number of subjects: 0
Study: 31880963

Group type: EXPERIMENTAL
Intervention: Erector Spinae Plane Block (ESPB)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional Analgesia (CA)
Number of subjects: 60
Study: 29398993

Group type: EXPERIMENTAL
Intervention: Pregabalin 150 mg daily
Number of subjects: 86

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 86
Study: 27537670

Group type: EXPERIMENTAL
Intervention: Virtual clinical simulation
Number of subjects: 56

Group type: COMPARATOR
Intervention: Face-to-face high fidelity manikin simulation
Number of subjects: 56
Study: 25295709

Group type: EXPERIMENTAL
Intervention: Procalcitonin (PCT) algorithm with 0.1 ng/ml cut-off
Number of subjects: 400

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Procalcitonin (PCT) algorithm
Number of subjects: 400
Study: 23768664

Group type: EXPERIMENTAL
Intervention: In-Home Cognitive Behavioral Therapy (IH-CBT)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Standard Home Visitation (SHV)
Number of subjects: 93
Study: 20799286

Group type: EXPERIMENTAL
Intervention: Mechanical bowel preparation (MBP)
Number of subjects: 42

Group type: COMPARATOR
Intervention: No mechanical bowel preparation (no-MBP)
Number of subjects: 42
Study: 18548362

Group type: EXPERIMENTAL
Intervention: Beta-alanine (4.8 g per day)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 15706558

Group type: EXPERIMENTAL
Intervention: Whole body vibration plus physical therapy (PT)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Physical therapy alone
Number of subjects: 42
Study: 12362285

Group type: EXPERIMENTAL
Intervention: IVUS guidance
Number of subjects: 43

Group type: COMPARATOR
Intervention: ANGIO guidance
Number of subjects: 43
Study: 9525795

Group type: EXPERIMENTAL
Intervention: Outreach case management services in addition to standard aftercare service
Number of subjects: 292

Group type: COMPARATOR
Intervention: Standard aftercare services only
Number of subjects: 292
Study: 7698053

Group type: EXPERIMENTAL
Intervention: 9 g of fish oil
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 18 g of fish oil
Number of subjects: 40

Group type: COMPARATOR
Intervention: 9 g of corn oil
Number of subjects: 40

Group type: COMPARATOR
Intervention: 18 g of corn oil
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Fish oil (both dosages)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Fish oil and corn oil
Number of subjects: 40
Study: 2655680

Group type: EXPERIMENTAL
Intervention: Intravenous methylprednisolone sodium succinate (MPSS) at doses of 20, 40, and 80 mg
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Oral methylprednisolone (20 mg as 4 x 5 mg tablets)
Number of subjects: 5
Study: 11717

Group type: EXPERIMENTAL
Intervention: Lorazepam (4 mg)
Number of subjects: 95

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 95

Group type: COMPARATOR
Intervention: Diazepam (10 mg)
Number of subjects: 95
Study: 31285821

Group type: EXPERIMENTAL
Intervention: WHO EBHR formulation with 0.5% glycerol
Number of subjects: 40

Group type: COMPARATOR
Intervention: WHO EBHR formulation without glycerol (0%)
Number of subjects: 40

Group type: COMPARATOR
Intervention: WHO EBHR formulation with 1.45% glycerol
Number of subjects: 40

Group type: COMPARATOR
Intervention: WHO EBHR formulation with 0.75% glycerol
Number of subjects: 40
Study: 27831503

Group type: EXPERIMENTAL
Intervention: cisplatin-paclitaxel plus CADI-05 (chemoimmunotherapy group)
Number of subjects: 221

Group type: COMPARATOR
Intervention: cisplatin-paclitaxel (chemotherapy group)
Number of subjects: 221
Study: 26432510

Group type: EXPERIMENTAL
Intervention: DHA-rich fish-oil supplementation during pregnancy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study: 23814241

Group type: EXPERIMENTAL
Intervention: NA-QS
Number of subjects: 100

Group type: COMPARATOR
Intervention: QS
Number of subjects: 100

Group type: COMPARATOR
Intervention: MP
Number of subjects: 100
Study: 21099725

Group type: EXPERIMENTAL
Intervention: Prednisolone within 24 hours
Number of subjects: 829

Group type: EXPERIMENTAL
Intervention: Prednisolone within 25 to 48 hours
Number of subjects: 829

Group type: COMPARATOR
Intervention: No prednisolone (control group) within 24 hours
Number of subjects: 829

Group type: COMPARATOR
Intervention: No prednisolone (control group) within 25 to 48 hours
Number of subjects: 829

Group type: EXPERIMENTAL
Intervention: Prednisolone for patients aged 40 years or older
Number of subjects: 829

Group type: EXPERIMENTAL
Intervention: Prednisolone for patients aged younger than 40 years
Number of subjects: 829
Study: 18851956

Group type: EXPERIMENTAL
Intervention: Atorvastatin (10 mg/day for 4 weeks)
Number of subjects: 136
Study: 17518508

Group type: COMPARATOR
Intervention: Cinacalcet (90 mg) alone
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Cinacalcet (90 mg) with ketoconazole (200 mg twice daily for 7 days)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Cinacalcet (90 mg) with ketoconazole
Number of subjects: 24
Study: 15451121

Group type: EXPERIMENTAL
Intervention: Treatment for nicotine dependence
Number of subjects: 211
Study: 11439378

Group type: EXPERIMENTAL
Intervention: Skin biopsy at the proximal thigh and distal leg in ganglionopathy patients
Number of subjects: 47

Group type: COMPARATOR
Intervention: Skin biopsy at the proximal thigh and distal leg in axonal neuropathy patients
Number of subjects: 47

Group type: COMPARATOR
Intervention: Skin biopsy at the proximal thigh and distal leg in healthy subjects
Number of subjects: 47
Study: 9879639

Group type: EXPERIMENTAL
Intervention: 14C-delmopinol mouth rinse (10-ml aqueous solution at 2 mg/ml)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 14C-delmopinol oral dose
Number of subjects: 12
Study: 8020806

Group type: EXPERIMENTAL
Intervention: Amino acid based diet containing 3% fat
Number of subjects: 40

Group type: COMPARATOR
Intervention: Peptide based diet containing 33% fat
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both diets
Number of subjects: 40
Study: 31742932

Group type: EXPERIMENTAL
Intervention: Nonabsorbable Merocel packs (packing type A)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Propel steroid eluting stents (packing type B)
Number of subjects: 40
Study: 29225152

Group type: EXPERIMENTAL
Intervention: Adenosine (postconditioning group)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 60
Study: 27634660

Group type: EXPERIMENTAL
Intervention: Sexual health care nursing record
Number of subjects: 24

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 24
Study: 24063263

Group type: EXPERIMENTAL
Intervention: Primary intraocular lens (IOL) implantation
Number of subjects: 40

Group type: COMPARATOR
Intervention: Secondary intraocular lens (IOL) implantation
Number of subjects: 40
Study: 22627166

Group type: EXPERIMENTAL
Intervention: Low dose haloperidol
Number of subjects: 498

Group type: EXPERIMENTAL
Intervention: Amisulpride
Number of subjects: 498

Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 498

Group type: EXPERIMENTAL
Intervention: Quetiapine
Number of subjects: 498

Group type: EXPERIMENTAL
Intervention: Ziprasidone
Number of subjects: 498

Group type: COMPARATOR
Intervention: All treatment groups
Number of subjects: 498
Study: 20141367

Group type: EXPERIMENTAL
Intervention: Alendronate 70 mg once weekly for 1 year
Number of subjects: 2

Group type: COMPARATOR
Intervention: Risedronate 35 mg once weekly for 1 year
Number of subjects: 2
Study: 19902897

Group type: EXPERIMENTAL
Intervention: Standard design NexGen Legacy Posterior-Stabilized TKA
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: High-flexion design NexGen Legacy Posterior-Stabilized TKA
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Soft tissue release
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Type of femoral component
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Preoperative and intraoperative range of flexion
Number of subjects: 56
Study: 17042906

Group type: EXPERIMENTAL
Intervention: Low amplitude vibration (30 Hz, 1.5 mm peak-to-peak amplitude)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: High amplitude vibration (30 Hz, 3 mm peak-to-peak amplitude)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Non-vibration condition (control)
Number of subjects: 9
Study: 12957560

Group type: COMPARATOR
Intervention: Healthy elderly adults walking over obstacles
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Elderly patients with balance disorders walking over obstacles
Number of subjects: 0
Study: 10969426

Group type: EXPERIMENTAL
Intervention: Weekly home-based intervention
Number of subjects: 171

Group type: COMPARATOR
Intervention: Control (brief monthly tracking visits)
Number of subjects: 171
Study: 9102666

Group type: EXPERIMENTAL
Intervention: Multiple insulin therapy
Number of subjects: 219

Group type: COMPARATOR
Intervention: Conventional insulin therapy
Number of subjects: 219

Group type: EXPERIMENTAL
Intervention: Hb A(1c) levels
Number of subjects: 219

Group type: EXPERIMENTAL
Intervention: Evolution time of IDDM
Number of subjects: 219
Study: 8416458

Group type: EXPERIMENTAL
Intervention: Ceftriaxone 250 mg IM
Number of subjects: 252

Group type: EXPERIMENTAL
Intervention: Amoxicillin 3 g orally plus probenecid 1 g orally
Number of subjects: 252

Group type: EXPERIMENTAL
Intervention: Spectinomycin 2 g IM
Number of subjects: 252
Study: 2877490

Group type: EXPERIMENTAL
Intervention: Colloidal bismuth subcitrate (CBS), 120 mg 4 times a day
Number of subjects: 43

Group type: COMPARATOR
Intervention: Cimetidine (C), 400 mg 3 times a day
Number of subjects: 43

Group type: COMPARATOR
Intervention: Cimetidine (C), 400 mg at meals plus 800 mg at bedtime
Number of subjects: 43
Study: 30173431

Group type: EXPERIMENTAL
Intervention: 100 U botulinum‐A toxin at 10 U/ml
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: 100 U botulin‐A toxin at 10 U/ml
Number of subjects: 70

Group type: COMPARATOR
Intervention: Saline control
Number of subjects: 70
Study: 26927315

Group type: EXPERIMENTAL
Intervention: Lifestyle intervention
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Weight reduction (1 kg)
Number of subjects: 151

Group type: COMPARATOR
Intervention: Control arm
Number of subjects: 151
Study: 25073131

Group type: EXPERIMENTAL
Intervention: Combined use of amplification and sound generator
Number of subjects: 49

Group type: COMPARATOR
Intervention: Conventional amplification alone
Number of subjects: 49
Study: 22712629

Group type: EXPERIMENTAL
Intervention: Memantine 5 mg once daily, titrated to 10 mg twice daily for 11 days, then DMQ 30 mg every 12 hours for 8 days
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: DMQ 30 mg every 12 hours for 8 days, then memantine titrated to 10 mg every 12 hours for 11 days
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Quinidine (part of DMQ)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Adverse events
Number of subjects: 52

Group type: COMPARATOR
Intervention: Pharmacodynamic variables
Number of subjects: 52
Study: 20154601

Group type: EXPERIMENTAL
Intervention: Arterial catheters
Number of subjects: 3532

Group type: COMPARATOR
Intervention: Central venous catheters
Number of subjects: 3532
Study: 18587135

Group type: EXPERIMENTAL
Intervention: IL-2 at 4.5 MIU twice daily in 5 day cycles
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: IL-2 at 7.5 MIU twice daily in 5 day cycles
Number of subjects: 36

Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Low-dose IL-2
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: High-dose IL-2
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: All groups (including control)
Number of subjects: 36
Study: 15891326

Group type: EXPERIMENTAL
Intervention: Active ITD on facemask
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Active ITD on ETT
Number of subjects: 13

Group type: COMPARATOR
Intervention: Sham ITD on facemask
Number of subjects: 13

Group type: COMPARATOR
Intervention: Sham ITD on ETT
Number of subjects: 13
Study: 11788552

Group type: EXPERIMENTAL
Intervention: 500 ml meat soup meal
Number of subjects: 40

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 40
Study: 9895382

Group type: EXPERIMENTAL
Intervention: PEG (13 g/sachet)
Number of subjects: 115

Group type: COMPARATOR
Intervention: Lactulose (10 g/sachet)
Number of subjects: 115
Study: 8562673

Group type: EXPERIMENTAL
Intervention: 0.8 ml/kg alcohol
Number of subjects: 8

Group type: COMPARATOR
Intervention: non-alcoholic drink
Number of subjects: 8
Study: 2371929

Group type: EXPERIMENTAL
Intervention: Famotidine (40 mg)
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Ranitidine (300 mg)
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Sodium citrate (30 ml)
Number of subjects: 114

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 114
Study: 7395881

Group type: EXPERIMENTAL
Intervention: Lidocaine iontophoresis
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Lidocaine infiltration
Number of subjects: 27

Group type: COMPARATOR
Intervention: Topical application of lidocaine or placebo
Number of subjects: 27
Study: 31987229

Group type: EXPERIMENTAL
Intervention: 500 mg/day of synbiotic for 8 weeks
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo for 8 weeks
Number of subjects: 60
Study: 31407653

Group type: EXPERIMENTAL
Intervention: Annual community-wide treatment (CWT) for four years
Number of subjects: 0

Group type: COMPARATOR
Intervention: Biennial school-based treatment (SBT) over four years
Number of subjects: 0
Study: 28300854

Group type: EXPERIMENTAL
Intervention: THVD-102 (oxybutynin 7.5 mg / pilocarpine 7.5 mg)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Oxybutynin 7.5 mg
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: THVD-102
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Oxybutynin
Number of subjects: 24
Study: 26529009

Group type: EXPERIMENTAL
Intervention: Cereal proteins (zein, gliadin, glutelin)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Legume proteins (soy, pea, lentil)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control (heme alone)
Number of subjects: 30
Study: 23640731

Group type: EXPERIMENTAL
Intervention: Upfront double-guidewire technique (DGT)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Standard cannulation technique (SCT)
Number of subjects: 50
Study: 21614940

Group type: EXPERIMENTAL
Intervention: Pulpa dentis D30 (PD)
Number of subjects: 32
Study: 19285658

Group type: EXPERIMENTAL
Intervention: Surgisis Inguinal Hernia Matrix (SIHM)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Polypropylene (PP)
Number of subjects: 70
Study: 16581983

Group type: EXPERIMENTAL
Intervention: rTMS applied to right dorsal extrastriate cortex in EB subjects
Number of subjects: 0

Group type: COMPARATOR
Intervention: rTMS targeting the same cortical areas in sighted subjects
Number of subjects: 0
Study: 15605184

Group type: EXPERIMENTAL
Intervention: IV/PO moxifloxacin (400 mg q.i.d.)
Number of subjects: 101

Group type: COMPARATOR
Intervention: IV/PO antimicrobial comparator agents
Number of subjects: 101
Study: 11408428

Group type: EXPERIMENTAL
Intervention: High-intensity training under hypoxic conditions
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Low-intensity training under hypoxic conditions
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: High-intensity training under normoxic conditions
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Low-intensity training under normoxic conditions
Number of subjects: 4

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 4
Study: 9005910

Group type: EXPERIMENTAL
Intervention: Postoperative epidural infusion of 5 microg/ml fentanyl
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Postoperative epidural infusion of 5 microg/ml fentanyl plus 0.125% bupivacaine at a rate of 10 ml per hour
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Active flexion and extension of the foot
Number of subjects: 19
Study: 8238138

Group type: EXPERIMENTAL
Intervention: Epidural analgesia
Number of subjects: 93

Group type: COMPARATOR
Intervention: Narcotic analgesia
Number of subjects: 93
Study: 3306943

Group type: EXPERIMENTAL
Intervention: Moxalactam (n = 29)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Clindamycin plus tobramycin (n = 31)
Number of subjects: 60
Study: 31229619

Group type: EXPERIMENTAL
Intervention: Oral GABA twice daily plus two injections of recombinant GAD enzyme
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Oral GABA plus placebo GAD injections
Number of subjects: 99

Group type: COMPARATOR
Intervention: Placebo GABA and placebo GAD
Number of subjects: 99
Study: 29485791

Group type: EXPERIMENTAL
Intervention: TEA with a mixture of levobupivacaine, fentanyl and adrenaline
Number of subjects: 60

Group type: COMPARATOR
Intervention: IV‐PCA with morphine
Number of subjects: 60
Study: 25604760

Group type: EXPERIMENTAL
Intervention: Community workshops, community involvement in clean-up campaigns, covering elevated containers, in-house rubbish disposal without larviciding, mobilization of schoolchildren and senior inhabitants, distribution of IEC materials
Number of subjects: 20

Group type: COMPARATOR
Intervention: Routine vector control activities
Number of subjects: 20
Study: 23243173

Group type: EXPERIMENTAL
Intervention: Vaginal clindamycin
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: Lactobacillus-vaginal probiotic
Number of subjects: 450

Group type: COMPARATOR
Intervention: Vaginal placebo
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: Same pre-/posttreatment sexual partner
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: Inconsistent condom use
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: Non-Australian
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: Estrogen-containing contraceptive
Number of subjects: 450
Study: 22254399

Group type: EXPERIMENTAL
Intervention: Model DBS
Number of subjects: 5

Group type: COMPARATOR
Intervention: Clinical DBS
Number of subjects: 5

Group type: COMPARATOR
Intervention: Off DBS
Number of subjects: 5
Study: 19811638

Group type: EXPERIMENTAL
Intervention: TAU plus the training (Future oriented group training)
Number of subjects: 0
Study: 16673803

Group type: EXPERIMENTAL
Intervention: Methyl aminolevulinate (MAL)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Aminolevulinic acid (ALA)
Number of subjects: 69
Study: 15657666

Group type: EXPERIMENTAL
Intervention: PTP injection into intersphincteric space and internal anal sphincter with guidance by endoanal ultrasound (Group A, n = 42)
Number of subjects: 82

Group type: COMPARATOR
Intervention: PTP injection into intersphincteric space and internal anal sphincter without guidance by endoanal ultrasound (Group B, n = 40)
Number of subjects: 82
Study: 11145794

Group type: EXPERIMENTAL
Intervention: Tacrolimus ointment (0.03% or 0.1%)
Number of subjects: 631

Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 631